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The Protein Kinase C Pathway
Is Required for Viability in Quiescence
in Saccharomyces cerevisiae
and rapid loss of viability, as judged by viability staining
(see the Supplementary Material available with this arti-
cle online). Hence, loss of viability of bck1 mutants is
either the cause of, or a consequence of, defects in
responding to nitrogen limitation.
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54-56 Dumbarton Road Bck1 is an upstream activator of Mpk1 [1, 2]. The
starvation defect of bck1 mutants may thus be due toGlasgow G11 6NU
United Kingdom the lack of Mpk1 activity. As shown in Figure 1A and
the Supplementary Material, we find that homozygous
diploid or haploid mpk1 mutants also lose viability
upon transfer to media lacking a nitrogen source, andSummary
to the same extent and with the same kinetics as do
the congenic bck1 mutants (Supplementary Material).Protein kinase C, encoded by PKC1, regulates con-
We conclude that the entire MAP kinase branch of thestruction of the cell surface in vegetatively growing
Pkc1 pathway is selectively required for viability uponyeast cells. Pkc1 in part acts by regulating Mpk1, a
nitrogen limitation and is independent of cell type.MAP kinase [1, 2]. Mutants lacking Bck1, a component
Starvation for nitrogen or carbon causes yeast to enterof the MAP kinase branch of the pathway, fail to re-
a quiescent state. We find that mutants defective in thespond normally to nitrogen starvation, which causes
Pkc1-MAP kinase pathway are also prone to die whenentry into quiescence [3, 4]. Given that the Tor1 and
starved of carbon (Figure S1A). Thus, the Pkc1-MAPTor2 proteins are key inhibitors of entry into quies-
kinase pathway is required to maintain viability uponcence [5], the Pkc1 pathway may regulate these pro-
both carbon and nitrogen limitation and is therefore un-teins. We find that pkc1 and mpk1 mutants rapidly
likely to be a sensor of either nutrient.die by cell lysis upon carbon or nitrogen starvation.
Pkc1 is the upstream activator of the Mpk1 kinaseThe Pkc1 pathway does not regulate the TOR proteins:
module and should also be required for viability upontranscriptional changes dependent on inhibition of the
starvation. Note: haploid pkc1 cells only grow vegeta-TORs occur normally in pkc1 and mpk1 mutants
tively in the presence of osmotic stabilization, whereaswhen starved for nitrogen; pkc1 and mpk1mutants
high osmolarity robustly suppresses the vegetativedie rapidly upon treatment with rapamycin, an inhibitor
growth and viability defects of mpk1 and bck1 mu-of the TORs. We find that Mpk1 is transiently activated
tants at high temperatures [8–10]. We find that the deathby rapamycin treatment via a novel mechanism. Fi-
of mpk1 mutants upon nitrogen or carbon starvationnally, we find that rapamycin treatment or nitrogen
is delayed in, and largely prevented by, the presence ofstarvation induces resistance to the cell wall-digesting
an osmotic-stabilizing agent (1 M sorbitol) (Figures 1Aenzyme zymolyase by a Pkc1-dependent mechanism.
and S1). However, we find that pkc1 mutants in theThus, the Pkc1 pathway is not a nutrient sensor but
presence of sorbitol (1 M) lose viability upon starvationacts downstream of TOR inhibition to maintain cell
(Figures 1A) and to a greater extent than do congenicintegrity in quiescence.
mpk1 cells (Figure 1A). We conclude that Pkc1 pro-
motes survival upon starvation by both Mpk1-depen-
Results and Discussion dent and Mpk1-independent mechanisms, the former
being largely suppressed by osmotic stabilization.
In mammalian cells, mTOR (the homolog of yeast TORs) It is possible that the Pkc1 pathway is required to
is regulated by protein kinase B, by amino acid levels inactivate the TORs upon both nitrogen and carbon limi-
via an unknown mechanism, and directly by cellular ATP tation. (Note: the Pkc1 pathway is unlikely to significantly
by virtue of its unusually high Km for that substrate (re- modulate TOR activity under vegetative growth condi-
viewed in [5–7]). In yeast, the TORs are inactivated when tions since mpk1 and pkc1mutants are neither super-
transferred to poor nitrogen or carbon sources or when sensitive nor resistant to the inhibitory growth effects of
starved for either nutrient [5]. The mechanisms regulat- rapamycin, assayed in the presence, and where possible
ing yeast TORs are not known. Given that bck1mutants the absence, of osmotic stabilization [S.A.K., unpub-
display a defect upon nitrogen starvation, we set out to lished data].) If the Pkc1 pathway is an inhibitor of the
investigate the possible role of Bck1 and the Pkc1-MAP TOR pathway, then transcriptional changes dependent
kinase pathway in regulating the TORs. on TOR inhibition should be delayed or prevented in
Mutants defective in the Pkc1 pathway are prone to Pkc1 pathway mutants when starved. Inhibition of the
die under a variety of stress conditions [1, 2]. It is there- TORs is sufficient to cause repression of the ribosomal
fore possible that bck1mutants also die upon nitrogen protein genes (e.g., RPL30 and RPS1a) and activation
limitation. When exponentially growing homozygous of the Gln3-dependent genes (e.g., GAP1 and MEP2). If
diploid bck1mutant cells were resuspended in medium these transcriptional outputs can serve as reporters of
lacking a nitrogen source, they showed a progressive TORs’ status in our experiments, then the ability of TOR
inhibition to cause these changes should be unaffected
in Pkc1 pathway mutants. We find that the two ribosomal1Correspondence: j.gray@bio.gla.ac.uk
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Figure 1. The Pkc1 Pathway Is Required for
Viability upon Carbon Starvation, Nitrogen
Starvation, and Rapamycin Treatment and
Does Not Regulate the TORs
(A) Yeast strains were grown in YPD (1%
Bacto-yeast extract, 2% Bacto-peptone, 2%
glucose) to midlogarithmic phase, transferred
to SD-N (0.17% Bacto-yeast nitrogen base,
2% glucose) at t  0, and incubated at 25C.
Media were supplemented with 1 M sorbitol
when necessary. Cell viability was deter-
mined by methylene blue staining. The per-
centage of viable cells was determined by
counting the number of cells that had re-
duced the dye versus the total number of
cells. Approximately 200 cells were counted
at each time point. At least three separate
experiments were performed, each in dupli-
cate or triplicate, and their overall averages
were determined. The graph shows the rela-
tive percent viability calculated by dividing
the percentage of viable cells at each time
point by the percentage viable at t  0 and
multiplying by 100. The average initial viability
for wild-type yeast (JVG718) was 99%; for
wild-type supplemented with 1 M sorbitol, it
was 100%; for pkc1 cells (JVG201) in 1 M
sorbitol, it was 57%; for mpk1 cells
(JVG216), it was 87.4%; and for mpk1 sup-
plemented with 1 M sorbitol, it was 97.3%.
Please note: (s) denotes cells grown in the
presence of sorbitol.
(B) Yeast were treated as in (A), except YP
broth (1% Bacto-yeast extract, 2% Bacto-
peptone) was used instead of SD-N broth.
Media were supplemented with 1 M sorbitol
when necessary. The average initial viability
for wild-type yeast (JVG718) was 99.7%; for
wild-type yeast supplemented with 1 M sorbi-
tol, it was 100%; for pkc1 cells (JVG201)
supplemented with 1 M sorbitol, it was
57.4%; for mpk1 cells (JVG216), it was
87.3%; and for mpk1 yeast supplemented
with 1 M sorbitol, it was 97.3%.
(C) Wild-type (JVG718) and pkc1 cells
(JVG201) were grown to midlogarithmic
phase in YPD supplemented with sorbitol (1 M), treated with a growth-inhibiting concentration of rapamycin (2 g/ml) or transferred to SD-
N supplemented with sorbitol (1 M), and incubated at 25C. Total RNA was prepared from each time point, 5 g of total RNA was loaded
onto each gel lane, and RNA was subjected to Northern analysis. Blots were probed for the RPS1a, RPL30, and GAP1 transcripts. A probe
for ACT1 was used as a loading control.
(D) Cells were grown to midlogarithmic phase in YPD (with or without sorbitol [1 M]), rapamycin was added to a growth-inhibiting concentration
of 0.2 g/ml, and cultures were incubated at 25C. Viability was determined as in (A). The average initial viability for wild-type yeast (JVG718)
was 100%; for wild-type supplemented with 1 M sorbitol, it was 100%; for pkc1 cells (JVG201) supplemented with 1 M sorbitol, it was 70%;
for mpk1 cells (JVG216), it was 92.8%; and for mpk1 cells supplemented with 1 M sorbitol, it was 97.3%.
protein genes examined, RPL30 and RPS1a, are strongly GAP1 and MEP2 occurred to the same extent and with
the same kinetics in pkc1 or mpk1 cells as in wild-and rapidly repressed and that the two Gln3-regulated
genes examined, GAP1 and MEP2, are strongly and type cells (Figure 1B; data not shown). We conclude
that the Pkc1 pathway does not act upstream of therapidly induced in wild-type cells treated with rapamycin
in rich media, both in the presence (Figure 1B) and ab- TORs in response to nitrogen starvation and infer that
the pathway is not part of a nutrient-sensing system.sence of sorbitol (data not shown). These transcriptional
changes also occur in pkc1 mutants in the presence If the Pkc1 pathway plays a critical role in quiescent
cells, then mutants defective in the Pkc1 pathway shouldof sorbitol (Figure 1B) and in mpk1 mutants in the
absence and presence of sorbitol (data not shown). We lose viability upon rapamycin treatment even in the pres-
ence of nutrients. We find that mutants defective in theconclude that the Pkc1 pathway does not mediate re-
pression of the ribosomal protein genes or activation of pathway rapidly lose viability upon treatment with rapa-
mycin (Figure 1C; data not shown). The Pkc1 pathwayGln3 in response to TOR inactivation.
We next monitored expression of RPL30, RPS1a, is thus required for viability upon carbon starvation, ni-
trogen starvation, and TOR inactivation in the presenceGAP1, and MEP2 upon nitrogen starvation. Repression
of the two ribosomal protein genes and activation of of nutrients, three conditions that cause cells to enter
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Figure 2. Mpk1 Is Activated by Rapamycin
Treatment Independently of the Putative Cell
Surface Sensors Hcs77/Wsc1 and Mid2
(A) Wild-type (JVG718), hcs77 (JVG337), and
mid2 (JVG1237) yeast were grown to midlo-
garithmic phase in YPD, treated with rapa-
mycin to a growth-inhibiting concentration of
2 g/ml, and incubated for 2 hr at 25C. Equal
numbers of cells were collected for each
sample. Protein was prepared and subjected
to Western blot analysis. The activation state
of Mpk1p was determined using an antibody
that recognizes the active dual-phosphory-
lated form of the protein (top blot). The same
blot was reprobed with an anti-Mpk1 anti-
body as a loading control (bottom blot).
(B) Wild-type yeast (JVG718) was grown and
treated with rapamycin as in (A). Protein sam-
ples were taken for Western blot analysis as
a function of time after the addition of rapa-
mycin and were processed as in (A). Equal
numbers of cells were collected at each time
point.
(C) Wild-type, pkc1, and hcs77mid2
yeast were grown to midlogarithmic phase in
YPD supplemented with sorbitol (1 M), then
transferred to SD-N medium (supplemented
with 1 M sorbitol) and incubated at 25C. Via-
bility was determined as in Figure 1A. The
average initial viability of wild-type yeast
(JVG718) was 99.4%. The average initial via-
bility for the hcs77mid2 mutant (JVG1331)
was 84%; for pkc1 cells (JVG201), it was
57% (as shown in Figure 1A). Note: (s) repre-
sents cells grown in the presence of sorbitol.
(D) Wild-type, pkc1, and hcs77mid2 cells
were grown to midlogarithmic phase in YPD
supplemented with sorbitol (1 M), treated with
rapamycin to a growth-inhibiting concentra-
tion of 2 g/ml, and incubated at 25C. The
average initial viability of wild-type cells
(JVG718) was 99.8%; for hcs77mid2 cells
(JVG1331), it was 67%; and for pkc1
cells (JVG201), it was 70%. Viability was de-
termined as in Figure 1A.
quiescence-like states. These data suggest that the surface sensors Hcs77/Wsc1 and Mid2 [12–16]. Unex-
pectedly, we find that Mpk1 is activated normally inPkc1 pathway is inherently required for the viability of
quiescent cells and that the pathway either acts down- hcs77 and in mid2 mutants when treated with rapa-
mycin (Figure 2A). Indeed, we find that hcs77 andstream of, or parallel to, TOR inhibition.
If the Pkc1-MAP kinase pathway acts downstream of mid2 single mutants remain largely viable in rapamycin
or when starved for nitrogen (data not shown). MutantsTOR inhibition, we might expect inactivation of the TORs
to activate Mpk1. The activation state of Mpk1 was de- lacking both receptors also remain largely viable upon
rapamycin treatment or nitrogen starvation (Figures 2Ctermined by Western blot analysis using an antibody
that specifically recognizes the dual-phosphorylated and 2D), in stark contrast to pkc1 mutants under the
same osmotically stabilized conditions (Figures 2C andand activated form of Mpk1 [11]. We find that Mpk1 is
activated by treatment of wild-type cells with rapamycin 2D). Note: mutants lacking both HCS77/WSC1 and MID2
are phenotypically similar to pkc1mutants; they remainand that the activation is transient, peaking at 2 hr after
drug treatment (Figures 2A and 2B). Mpk1 is only weakly viable and proliferate only when osmotically stabilized.
We conclude that Hcs77/Wsc1 and Mid2 are not re-activated at earlier time points tested, specifically 30
min and 1 hr (data not shown). These data strongly quired for Pkc1 activity in quiescent cells. Our data sug-
gest that the Pkc1 pathway is activated in response toindicate that the Pkc1-MAP kinase pathway acts down-
stream of TOR inhibition during entry into quiescence. loss of TOR activity via a novel mechanism independent
of that used to sense cell surface stress.The Pkc1-MAP kinase pathway is activated in re-
sponse to a variety of stresses to the cell surface, pre- What is the role of the Pkc1 pathway in quiescent
cells? It is possible that the pathway regulates polaritydominantly via one or the other of the putative cell
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of the actin cytoskeleton in quiescence [17]. However,
we find that the actin cytoskeleton is indistinguishable
in wild-type, pkc1, or mpk1 cells upon treatment with
rapamycin or upon starvation for nitrogen or carbon, as
judged by rhodamine-phalloidin staining (S.A.K., unpub-
lished data).
The Pkc1 pathway maintains cell integrity during veg-
etative growth and upon heat shock [1, 2]. Therefore,
we examined if pkc1 and mpk1 cells also lyse when
treated with rapamycin. The fraction of lysed cells was
determined by the uptake of propidium iodide, a mem-
brane-impermeable dye. We find that both mpk1 and
pkc1 cells are prone to lyse upon rapamycin treatment,
lysis being concomitant with the loss of cell viability as
judged by methylene blue staining (Figures 1C and 3A).
These data suggest that the Pkc1 pathway is required
to maintain cell integrity in quiescence.
The mechanism by which Mpk1 maintains cell surface
integrity during vegetative growth is poorly understood.
The transcription factors, Rlm1 and Swi4, act down-
stream of Mpk1 and are required for most, if not all, of
the gene expression changes caused by the activation
of Mpk1 [18, 19]. We find that rlm1mutants lose viabil-
ity to some extent upon rapamycin treatment, although
the defect is not as severe as that of congenic mpk1
mutants (Figure 3B). This death of rlm1mutants is fully
suppressed by osmotic stabilization (data not shown). In
contrast, we find that swi4mutants do not appreciably
lose viability upon rapamycin treatment (Figure 3B).
These findings imply that Mpk1 promotes cell survival
in quiescence partly, but not wholly, via activating the
transcription factor Rlm1. It is thus likely that the Pkc1
pathway maintains the integrity of vegetatively growing
and quiescent states via the same downstream targets.
In agreement with this possibility, overexpression of
SWI4 can suppress the viability defect of mpk1 mu-
tants at high temperatures [19] and upon rapamycin
treatment (Figure 3C). Evidently, the requirement for the
Pkc1 pathway is more stringent in quiescent cells.
Starved (and thus quiescent) yeast cells display in-
creased resistance to zymolyase, a cell wall-degrading
enzyme cocktail. We find that wild-type cells acquire
resistance to zymolyase digestion upon rapamycin
treatment or nitrogen starvation and in the presence
(Figure 4A) or absence (data not shown) of sorbitol. We
Figure 3. The Pkc1 Pathway Is Required for Cell Integrity in Quies- infer that inhibition of the TORs is sufficient to remodel
cence Partly via the Rlm1 Transcription Factor
the cell surface during entry into quiescence. As shown
(A) Cells (haploid wild-type [JVG718], haploid pkc1 [JVG201], wild- in Figure 4B, pkc1 cells do not acquire resistance to
type diploid [JVG720], and homozygous mpk1 diploid [JVG212])
zymolyase upon rapamycin treatment or nitrogen star-were grown in YPD (when necessary with sorbitol [1 M]) to midlogar-
vation in the presence of sorbitol. In contrast, mpk1ithmic phase, then rapamycin was added to a growth-inhibiting con-
mutants efficiently acquire resistance to zymolyasecentration of 0.2 g/ml and cultures were incubated at 25C for 5
hr. The uptake of propidium iodide, a membrane-impermeable dye, upon the same treatments (data not shown). We con-
was monitored before and after treatment with rapamycin. clude that Pkc1 is required to maintain cell integrity in
(B) Wild-type, rlm1, mpk1, and swi4 cells were grown to midlo- quiescence by both Mpk1-dependent and Mpk1-inde-
garithmic phase in YPD, treated with rapamycin to a final concentra-
pendent mechanisms and that Pkc1 is required to ac-tion of 2 g/ml, and incubated at 25C. The average initial viability
tively remodel the cell surface independently of Mpk1.for wild-type cells (JVG718; strain EG123) was 98.2%; for rlm1
cells (JVG1373; strain EG123), it was 98.9%; and for mpk1 cells
(JVG216; strain EG123), it was 92.8%. The average initial viability
for wild-type cells (JVG956; strain S288C) was 98.2%; for swi4 The resulting transformants were grown to midlogarithmic phase in
cells (JVG970; strain S288C), it was 93.5%; and for mpk1 cells SD-URA. The cells were treated with rapamycin to a growth-inhib-
(JVG331; strain S288C), it was 95.9%. Viability was determined as iting concentration of 2 g/ml and were incubated at 25C. The
in Figure 1A. average initial viability for cells with the vector was 67.1%; for cells
(C) Homozygous diploid mpk1 cells were transformed with a high- overexpressing SWI4, it was 100%. Viability was determined as in
copy plasmid containing SWI4 or with the vector control (YEp24). Figure 1A.
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Figure 4. Inhibition of the TORs Is Sufficient
to Cause Cell Surface Remodeling by a Pkc1-
Dependent Mechanism
(A) Wild-type cells (JVG718) were grown in
YPD supplemented with sorbitol (1 M) to mid-
logarithmic phase and were incubated in
YPD, YPD  2 g/ml rapamycin, or SD-N, all
supplemented with sorbitol (1 M), for 3 hr at
25C. Cells were treated with 50 U/ml zymoly-
ase 20T, and the optical density of the culture
was monitored as a function of time after the
addition of the enzyme cocktail. At least three
separate experiments were performed in trip-
licate, and the overall averages were deter-
mined. The graphs show the relative OD600nm,
which is calculated by dividing the OD600nm at
each time point by the initial OD600nm reading.
(B) pkc1 mutant cells (JVG201) were grown
in YPD supplemented with sorbitol (1 M) and
were transferred to YPD (filled circle), YPD 
2 g/ml rapamycin (filled square), or SD-N
(filled triangle), all supplemented with sorbitol
(1 M), for 3 hr at 25C. Cells were digested
with zymolyase, and the relative OD600nm was
determined as in (A).
(C) A proposed model. The TOR proteins are
inactivated by nutrient limitation or upon ra-
pamycin (Rap) treatment. This inactivation of
the TORs induces the quiescence program
(including repression of the ribosomal protein
genes and activation of Gln3-dependent
genes). Inactivation of the TORs also acti-
vates Pkc1, which is required to remodel the
cell surface by both Mpk1-dependent and
Mpk1-independent mechanisms. Inactiva-
tion of the TORs may directly or indirectly
cause changes to the actin cytoskeleton that
mediates activation of Pkc1. The cell surface
sensors Hcs77/Wsc1 and Mid2 are not in-
volved in Pkc1 activation during entry into
quiescence.
In summary, the Pkc1 pathway is not a nutrient sensor treatment (S.A.K., unpublished data). Third, pkc1 and
mpk1mutants die rapidly when treated with latrunculin(Figure 4C). Rather, we find a unique role for the path-
way: it is selectively required for the integrity (and conse- B, and this death is concomitant with cell lysis (S.A.K.,
unpublished data), as is the case for rapamycin treat-quently the viability) of quiescent cells. The increased
requirement for the pathway in quiescence is not due ment. Clarification of the role of actin changes during
entry into quiescence awaits the discovery of mutantsto the pathway affecting novel downstream targets. The
Pkc1 pathway acts downstream of TOR inhibition to specifically defective in actin-mediated activation of the
Pkc1 pathway.maintain cell integrity and to remodel the cell surface
during entry into quiescence. The pathway is activated
Supplementary Materialby TOR inhibition by a novel mechanism.
Supplementary Material including the Experimental Procedures andActivation of the Pkc1 pathway by rapamycin treat-
a figure showing the viability of homozygous diploid mutants lackingment is independent of the cell surface sensors Hcs77/
Bck1 or Mpk1 (in the presence or absence of sorbitol) upon starva-
Wsc1 and Mid2. How then is the pathway activated? tion for nitrogen or carbon is available at http:/images.cellpress.
Recent work by Harrison et al. [20] on the morphogenetic com/supmat/supmatin.htm.
checkpoint in yeast indicates that the Pkc1 pathway can
be activated by defects in the actin cytoskeleton (e.g., Acknowledgments
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